Köhler G, Lembke S, Brachmann K, Foth D, Happke S
Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Bereichs Medizin, Ernst-Moritz-Arndt-Universität Greifswald.
Zentralbl Gynakol. 1989;111(12):807-10.
The effects of the progestational compound dienogest (17 alpha-cyanomethyl-17 beta-hydroxy-estra-4,9-dien-3-one) on liver metabolism have been studied in 101 otherwise healthy women with endoscopically proven endometriosis. The women aged 17 to 45 years were treated with 2 mg dienogest in tablet form daily for 24 weeks. Aspartate amino transferase (ASAT), alanine amino transferase (ALAT), gamma glutamate transferase (GGT), alkaline phosphatase (AP), lactate dehydrogenase (LDH), and total bilirubin (BILI) were determined in serum before and after 1, 3 and 6 months use of the progestin. During the therapy period no deviations from the normal ranges were found. There was a slight significant decrease of ASAT and ALAT and a slight significant increase of LDH and BILI (p less than 0.05) remaining within the normal laboratory values. Since no undesirable metabolic side-effects have so far been observed with dienogest, it may be considered an effective new alternative treatment for endometriosis.
已对101名经内镜检查证实患有子宫内膜异位症的健康女性研究了孕激素类化合物地诺孕素（17α-氰甲基-17β-羟基-雌甾-4,9-二烯-3-酮）对肝脏代谢的影响。这些年龄在17至45岁的女性每天口服2毫克地诺孕素片，持续24周。在使用孕激素1、3和6个月前后，测定血清中的天冬氨酸氨基转移酶（ASAT）、丙氨酸氨基转移酶（ALAT）、γ-谷氨酸转移酶（GGT）、碱性磷酸酶（AP）、乳酸脱氢酶（LDH）和总胆红素（BILI）。在治疗期间，未发现超出正常范围的情况。ASAT和ALAT略有显著下降，LDH和BILI略有显著上升（p<0.05），但仍在正常实验室值范围内。由于迄今为止尚未观察到地诺孕素产生不良的代谢副作用，因此可将其视为治疗子宫内膜异位症的一种有效的新替代疗法。
